Literature DB >> 12551933

Synthesis and functional analyses of nuclear clusterin, a cell death protein.

Konstantin S Leskov1, Dmitry Y Klokov, Jing Li, Timothy J Kinsella, David A Boothman.   

Abstract

Nuclear clusterin (nCLU) is an ionizing radiation (IR)-inducible protein that binds Ku70, and triggers apoptosis when overexpressed in MCF-7 cells. We demonstrate that endogenous nCLU synthesis is a product of alternative splicing. Reverse transcriptase-PCR analyses revealed that exon II, containing the first AUG and encoding the endoplasmic reticulum-targeting peptide, was omitted. Exons I and III are spliced together placing a downstream AUG in exon III as the first available translation start site. This shorter mRNA produces the 49-kDa precursor nCLU protein. Ku70 binding activity was localized to the C-terminal coiled-coil domain of nCLU. Leucine residues 357, 358, and 361 of nCLU were necessary for Ku70-nCLU interaction. The N- and C-terminal coiled-coil domains of nCLU interacted with each other, suggesting that the protein could dimerize or fold. Mutation analyses indicate that the C-terminal NLS was functional in nCLU with the same contribution from N-terminal NLS. The C-terminal coiled-coil domain of nCLU was the minimal region required for Ku binding and apoptosis. MCF-7 cells show nuclear as well as cytoplasmic expression of GFP-nCLU in apoptotic cells. Cytosolic aggregation of GFP-nCLU was found in viable cells. These results indicate that an inactive precursor of nCLU exists in the cytoplasm of non-irradiated MCF-7 cells, translocates into the nucleus following IR, and induces apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551933     DOI: 10.1074/jbc.M209233200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  108 in total

1.  CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.

Authors:  Konstantin S Leskov; Shinako Araki; John-Paul Lavik; Jose A Gomez; Vivian Gama; Efstathios S Gonos; Ioannis P Trougakos; Shigemi Matsuyama; David A Boothman
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

3.  Increased clusterin expression in Fuchs' endothelial dystrophy.

Authors:  Ula V Jurkunas; Maya S Bitar; Ian Rawe; Deshea L Harris; Kathryn Colby; Nancy C Joyce
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-31       Impact factor: 4.799

4.  Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.

Authors:  Amina Zoubeidi; Kim Chi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression.

Authors:  Sabina Pucci; Paola Mazzarelli; Mazzarelli Paola; Fabiola Sesti; Sesti Fabiola; David A Boothman; Boothman A David; Luigi G Spagnoli; Spagnoli G Luigi
Journal:  Cell Cycle       Date:  2009-02-18       Impact factor: 4.534

Review 6.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

7.  Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation.

Authors:  Hakryul Jo; Yonghui Jia; Kulandayan K Subramanian; Hidenori Hattori; Hongbo R Luo
Journal:  Mol Cell Biol       Date:  2008-05-05       Impact factor: 4.272

8.  Advances and challenges in basic and translational research on clusterin.

Authors:  Ioannis P Trougakos; Julie Y Djeu; Efstathios S Gonos; David A Boothman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  Effects of clusterin over-expression on metastatic progression and therapy in breast cancer.

Authors:  Louise Flanagan; Lorna Whyte; Namita Chatterjee; Martin Tenniswood
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

10.  Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Authors:  Adriana Aguilar-Mahecha; Christiane Cantin; Maureen O'Connor-McCourt; Andre Nantel; Mark Basik
Journal:  Proteome Sci       Date:  2009-04-06       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.